Sister Projects

INTERCEPT collaborates closely with the PROMISE Consortium, building upon its pioneering work.

What is PROMISE?

The PROMISE Consortium (Prediction and Prevention through Omics, Microbiome, Immune System, and Environment) - comprising the Icahn School of Medicine at Mount Sinai in the United States (an INTERCEPT partner), Mass General Brigham in the United States and Sinai Health in Canada and funded by The Leona M. and Harry B. Helmsley Charitable Trust – was the first initiative of its kind to explore predictive and preventive factors in Crohn’s disease through:

Advanced omics

Microbiome analysis

Immunology

Environmental studies

The PROMISE study focuses on analysing and comparing blood-based biomarkers in healthy individuals before disease onset to those who remain disease-free. The objective is to identify early biomarkers enabling proactive intervention before symptoms emerge.

How INTERCEPT and PROMISE work together

By collaborating, INTERCEPT and PROMISE are:

Expanding biomarker validation across larger and more diverse populations.

Building on proven research to accelerate breakthroughs in early detection and prevention.

Making prevention and early diagnosis a reality – bringing us closer to stopping Crohn’s before it even starts.

INTERCEPT is more than a research project. It is movement toward a future without Crohn’s disease. By combining science, technology and global collaboration, we are unlocking the potential of biomarkers, early intervention and preventive treatments to transform the future of chronic disease care.